Developer docs
API playgroundTry for free, no card

Search company profiles

Omniscient Neurotechnology

Full company profile

uuid0000s3i

Namestring
Omniscient Neurotechnology
Legal namestring
Omniscient Neurotechnology
Websiteurl
o8t.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Omniscient Neurotechnology (o8t) is a Sydney-based medical software company founded in 2019 that develops Quicktome, an FDA-cleared, cloud-hosted (AWS) AI platform for connectomic brain mapping. The product ingests MRI and resting-state functional MRI scans and applies proprietary Constrained Spherical Deconvolution (CSD) tractography algorithms to produce personalized structural and functional brain network maps used in pre-surgical planning and neuroscience research. The platform is SOC 2 Type II certified and protected by a portfolio of 37 USPTO patents, with the underlying science documented across 93 peer-reviewed publications.

The company sells primarily to neurosurgeons and neuroscience researchers at large academic medical centers and specialty hospitals across the US, Australia, and other markets, using an enterprise SaaS go-to-market supported by a global distributor network. Named customers include Mount Sinai, Macquarie University Hospital, University of Miami Hospital, Miami Neuroscience Institute, WVU Medicine, UAMS, and the Jacobs Institute. Reimbursement economics have been substantially de-risked by the establishment of Category III CPT code 1039T, effective July 2026, which creates a formal US payment pathway for AI connectomic brain mapping.

The business is led by CEO Stephen Scheeler (formerly Facebook ANZ), co-founder and CMO Dr. Michael Sughrue (neurosurgeon), co-founder and CTO Dr. Stephane Doyen, COO Rob Malcolm, CFO Adam Fraser, and CCO Todd Smalley. To date, the company has raised approximately $70M+ across Series A through an oversubscribed Series D, with the May 2026 $27.2M round funding US commercial expansion and a new Sydney Connectomics Center of Excellence.

Short descriptiontext

Omniscient Neurotechnology (o8t) develops Quicktome, an FDA-cleared, cloud-hosted AI platform that converts MRI data into personalized brain network maps for neurosurgeons and neuroscience researchers at hospitals and academic medical centers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
connectomic analysis software, AI brain mapping platform, neurosurgical planning software, MRI tractography software, medical imaging SaaS
Industry2 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuroimaging Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Quicktome SaaS Platform Subscription
TypeSubscription Recurring
Description

Omniscient generates revenue through a software-as-a-service model, providing healthcare institutions with cloud-based access to the Quicktome connectomic analysis platform. The platform supports cranial surgery, neuro-oncology, and stroke applications, with reimbursement established via CPT code 1039T for connectomic analysis in the US healthcare system.

globenewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Enterprise hospital and research institution licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed. Sales cycle targets large hospital systems and research institutions via enterprise field sales.

globenewswire.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Quicktome
Description

AI-powered connectomic analysis platform that provides clinicians with detailed insights into patient-specific brain networks and function. Automatically analyzes MRI and resting-state fMRI data with AI-enabled post-processing to support individualized treatment planning.

o8t.com
+1 more record
Core offering1 text field

Omniscient Neurotechnology develops and sells Quicktome, an FDA-cleared AI-powered connectomic analysis platform that automatically processes MRI and resting-state functional MRI (rs-fMRI) scans to generate personalized brain network maps (connectomes) for neurosurgeons and neuroscience researchers. The cloud-based software supports cranial surgery, neuro-oncology, stroke, and movement disorders planning, with reimbursement established via CPT code 1039T in the US healthcare system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • MRI image processing reduced from hours of manual intervention to under 2 hours with less than 5 minutes of direct surgeon intervention
+1 more record
Product overview1 text field

Omniscient Neurotechnology offers the Quicktome platform, an AI-powered connectomic analysis platform. The core product, Quicktome, provides clinicians with detailed insights into patient-specific brain networks by automatically analyzing MRI and rs-fMRI data. The company also offers Quicktome FC (Functional Connectome), an FDA-cleared module that maps functional connectivity. Quicktome serves two primary segments: neurosurgeons who use it for pre-surgical planning, and researchers who use it for neural data analysis. The platform generates personalized brain maps and is deployed at major hospitals and research institutions worldwide.

Product and service4 records
1Quicktome
CategoryCore Platform
Description

AI-powered connectomic analysis platform that provides clinicians with detailed insights into patient-specific brain networks and function. Automatically analyzes millions of data points derived from MRI and resting-state functional MRI (rs-fMRI) with AI-enabled post-processing to support individualized treatment planning.

2Quicktome FC (Functional Connectome)
CategoryProduct Module
Description

FDA-cleared AI brain-mapping software that maps functional connectivity of a patient's unique networks, generating individualized neural network templates for surgical planning and functional analysis.

3Quicktome for Neurosurgeons
CategorySegment Offering
Description

Delivers precise knowledge of a patient's unique brain networks for actionable surgical insights prior to life-changing surgery. Helps neurosurgeons personalize treatment plans rather than relying on generalized anatomical diagrams.

4Quicktome for Researchers
CategorySegment Offering
Description

Platform that processes vast quantities of neural data to provide invaluable structural and functional information specific to each subject for neuroscience research applications.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-24
Description

Strategic partnership to launch the Connectomics Innovation Program, aiming to integrate connectomics into clinical practice and research. The program focuses on neurological conditions including stroke, coma, and neurologic deficits, leveraging Omniscient's AI-powered Quicktome platform. This partnership represents Omniscient's most significant clinical co-development alliance.

Strategic tierCoreTypeTechnology or Integration
Description

Omniscient's cloud-based Quicktome platform runs on AWS cloud infrastructure. AWS highlighted the company as a startup case study, with CTO Stephane Doyen featured in AWS startup content and Werner Vogels (VP & CTO of Amazon.com) writing about Omniscient's unique cloud-based technology. The cloud architecture enables scalable processing of MRI data.

3Global Distribution Partners
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Omniscient has several distribution partners globally, listed on the Quicktome Distributors page. These partners cover regions where the company does not have direct sales presence, enabling market reach across multiple geographic territories.

o8t.com
4Human Connectome Project
Strategic tierSupportingTypeTechnology or Integration
Description

Omniscient's research and brain mapping technology is built upon data from the Human Connectome Project, which provides the foundational neuroimaging datasets used to develop and validate the company's connectomic analysis methods and brain network parcellations.

o8t.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Omniscient Neurotechnology

Neuroimaging Softwareo8t.com

Omniscient Neurotechnology (o8t) develops Quicktome, an FDA-cleared, cloud-hosted AI platform that converts MRI data into personalized brain network maps for neurosurgeons and neuroscience researchers at hospitals and academic medical centers globally.

What Omniscient Neurotechnology does

Omniscient Neurotechnology (o8t) is a Sydney-based medical software company founded in 2019 that develops Quicktome, an FDA-cleared, cloud-hosted (AWS) AI platform for connectomic brain mapping. The product ingests MRI and resting-state functional MRI scans and applies proprietary Constrained Spherical Deconvolution (CSD) tractography algorithms to produce personalized structural and functional brain network maps used in pre-surgical planning and neuroscience research. The platform is SOC 2 Type II certified and protected by a portfolio of 37 USPTO patents, with the underlying science documented across 93 peer-reviewed publications.

The company sells primarily to neurosurgeons and neuroscience researchers at large academic medical centers and specialty hospitals across the US, Australia, and other markets, using an enterprise SaaS go-to-market supported by a global distributor network. Named customers include Mount Sinai, Macquarie University Hospital, University of Miami Hospital, Miami Neuroscience Institute, WVU Medicine, UAMS, and the Jacobs Institute. Reimbursement economics have been substantially de-risked by the establishment of Category III CPT code 1039T, effective July 2026, which creates a formal US payment pathway for AI connectomic brain mapping.

The business is led by CEO Stephen Scheeler (formerly Facebook ANZ), co-founder and CMO Dr. Michael Sughrue (neurosurgeon), co-founder and CTO Dr. Stephane Doyen, COO Rob Malcolm, CFO Adam Fraser, and CCO Todd Smalley. To date, the company has raised approximately $70M+ across Series A through an oversubscribed Series D, with the May 2026 $27.2M round funding US commercial expansion and a new Sydney Connectomics Center of Excellence.

Omniscient Neurotechnology firmographics

Firmographics
Name
Omniscient Neurotechnology
Legal name
Omniscient Neurotechnology
Website
https://o8t.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Omniscient Neurotechnology (o8t) develops Quicktome, an FDA-cleared, cloud-hosted AI platform that converts MRI data into personalized brain network maps for neurosurgeons and neuroscience researchers at hospitals and academic medical centers globally.
Ownership category
akta.pro rank

Omniscient Neurotechnology industry classification

Industry
Product category
Neuroimaging Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Connectomic analysis software
  • AI brain mapping platform
  • Neurosurgical planning software
  • MRI tractography software
  • Medical imaging SaaS

Where Omniscient Neurotechnology is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Omniscient Neurotechnology business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Quicktome SaaS Platform Subscription: Omniscient generates revenue through a software-as-a-service model, providing healthcare institutions with cloud-based access to the Quicktome connectomic analysis platform. The platform supports cranial surgery, neuro-oncology, and stroke applications, with reimbursement established via CPT code 1039T for connectomic analysis in the US healthcare system.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise hospital and research institution licensing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Omniscient Neurotechnology product offering

Product offering

Core offering

Omniscient Neurotechnology develops and sells Quicktome, an FDA-cleared AI-powered connectomic analysis platform that automatically processes MRI and resting-state functional MRI (rs-fMRI) scans to generate personalized brain network maps (connectomes) for neurosurgeons and neuroscience researchers. The cloud-based software supports cranial surgery, neuro-oncology, stroke, and movement disorders planning, with reimbursement established via CPT code 1039T in the US healthcare system.

Product overview

Omniscient Neurotechnology offers the Quicktome platform, an AI-powered connectomic analysis platform. The core product, Quicktome, provides clinicians with detailed insights into patient-specific brain networks by automatically analyzing MRI and rs-fMRI data. The company also offers Quicktome FC (Functional Connectome), an FDA-cleared module that maps functional connectivity. Quicktome serves two primary segments: neurosurgeons who use it for pre-surgical planning, and researchers who use it for neural data analysis. The platform generates personalized brain maps and is deployed at major hospitals and research institutions worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Quicktome: AI-powered connectomic analysis platform that provides clinicians with detailed insights into patient-specific brain networks and function. Automatically analyzes MRI and resting-state fMRI data with AI-enabled post-processing to support individualized treatment planning.
  • Quicktome FC (Functional Connectome)

Products and services

  • Quicktome AI-powered connectomic analysis platform that provides clinicians with detailed insights into patient-specific brain networks and function. Automatically analyzes millions of data points derived from MRI and resting-state functional MRI (rs-fMRI) with AI-enabled post-processing to support individualized treatment planning.
  • Quicktome FC (Functional Connectome) FDA-cleared AI brain-mapping software that maps functional connectivity of a patient's unique networks, generating individualized neural network templates for surgical planning and functional analysis.
  • Quicktome for Neurosurgeons Delivers precise knowledge of a patient's unique brain networks for actionable surgical insights prior to life-changing surgery. Helps neurosurgeons personalize treatment plans rather than relying on generalized anatomical diagrams.
  • Quicktome for Researchers Platform that processes vast quantities of neural data to provide invaluable structural and functional information specific to each subject for neuroscience research applications.

Quantifiable outcome

  • MRI image processing reduced from hours of manual intervention to under 2 hours with less than 5 minutes of direct surgeon intervention
  • +1 more outcomes

Companies that use Omniscient Neurotechnology

Customer profile

Named customers7 records

Segments1 record

Ideal customer profiles2 records

Omniscient Neurotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Omniscient Neurotechnology partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • The Jacobs Institute, Inc.coreStrategic or Co-development Partner · 24 July 2025Strategic partnership to launch the Connectomics Innovation Program, aiming to integrate connectomics into clinical practice and research. The program focuses on neurological conditions including stroke, coma, and neurologic deficits, leveraging Omniscient's AI-powered Quicktome platform. This partnership represents Omniscient's most significant clinical co-development alliance.
  • AWS (Amazon Web Services)coreTechnology or IntegrationOmniscient's cloud-based Quicktome platform runs on AWS cloud infrastructure. AWS highlighted the company as a startup case study, with CTO Stephane Doyen featured in AWS startup content and Werner Vogels (VP & CTO of Amazon.com) writing about Omniscient's unique cloud-based technology. The cloud architecture enables scalable processing of MRI data.
  • Global Distribution PartnerssupportingChannel Partner/ Reseller/ DistributorOmniscient has several distribution partners globally, listed on the Quicktome Distributors page. These partners cover regions where the company does not have direct sales presence, enabling market reach across multiple geographic territories.
  • Human Connectome ProjectsupportingTechnology or IntegrationOmniscient's research and brain mapping technology is built upon data from the Human Connectome Project, which provides the foundational neuroimaging datasets used to develop and validate the company's connectomic analysis methods and brain network parcellations.

Scale indicators9 records

Recent moves8 records

Expansion highlights1 record

Omniscient Neurotechnology competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

Omniscient Neurotechnology social profiles

Digital presence

Omniscient Neurotechnology compliance and trust

Trust signal

Compliance2 records

Omniscient Neurotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Omniscient Neurotechnology leadership team

Management profile

Number of profiles

Profiles6 records

Omniscient Neurotechnology funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Omniscient Neurotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omniscient Neurotechnology

What does Omniscient Neurotechnology do?

Omniscient Neurotechnology develops and sells Quicktome, an FDA-cleared AI-powered connectomic analysis platform that automatically processes MRI and resting-state functional MRI (rs-fMRI) scans to generate personalized brain network maps (connectomes) for neurosurgeons and neuroscience researchers. The cloud-based software supports cranial surgery, neuro-oncology, stroke, and movement disorders planning, with reimbursement established via CPT code 1039T in the US healthcare system.

Is Omniscient Neurotechnology a public or private company?

Omniscient Neurotechnology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Omniscient Neurotechnology founded?

Omniscient Neurotechnology was founded in 2019. It employs 51 to 100 people.

Where is Omniscient Neurotechnology based?

Omniscient Neurotechnology is headquartered in Sydney, Australia, in the Oceania region.

How does Omniscient Neurotechnology make money?

One revenue line is on record: quicktome SaaS Platform Subscription.

Does Omniscient Neurotechnology have an API?

No public API is recorded for Omniscient Neurotechnology.

What industry is Omniscient Neurotechnology in?

Omniscient Neurotechnology's product category is Neuroimaging Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceOmniscient Secures Third FDA Clearance, Extending Its Connectomic Platform into the Fast-Growing Deep Brain Stimulation MarketOmniscient received FDA 510(k) clearance for its Quicktome Deep Brain workflow, its third FDA clearance. The workflow localizes DBS leads to patient anatomy, targeting the growing DBS market with ~10,000 U.S. procedures annually. The company aims to expand its connectomic platform across neurosurgery and neurology.FinancialContent Business PageOmniscient Secures Third FDA Clearance, Extending Its Connectomic Platform into the Fast-Growing Deep Brain Stimulation MarketOmniscient received third FDA 510(k) clearance for Quicktome Deep Brain, a workflow applying connectomic analysis to deep brain stimulation. The clearance targets the DBS market, with about 10,000 new procedures annually in the U.S. The platform aims to standardize care across neurosurgery and neurology.FinancialContent Business PageWater Tower Research Publishes Report on Omniscient Neurotechnology Pty Limited, "Making Brain Data Actionable at Scale; Revolutionizing Brain Health"Water Tower Research published a report on Sydney-based neuroscience software firm Omniscient Neurotechnology, which commercializes connectomic analysis and visualization via its cloud-based Quicktome product. The company reported roughly $5 million in annual recurring revenue across 58 contracts as of July 2026, with a deep brain stimulation 510(k) submission expected cleared by year-end.Information AgeNRFC invests $20m in AI neurotech firm OmniscientAustralia's National Reconstruction Fund Corporation has invested $20 million in neuroscience AI startup Omniscient Neurotechnology as part of a $36 million Series D funding round, co-led with OIF Ventures. Omniscient's FDA-approved platform Quicktome uses AI to generate personalized brain maps from MRI scans, enabling neurosurgeons to tailor treatment plans. The company plans to establish a connectomics center of excellence in Sydney, creating 40 new highly skilled jobs in AI, neuroscience, and product development.SmartCompanyNRF leads $36 million raise for AI brain mapping startup OmniscientThe National Reconstruction Fund has invested $20 million in Australian neuroscience startup Omniscient Neurotechnology as part of a $36 million Series D round co-led with OIF Ventures. Omniscient uses artificial intelligence to map individual brain connections from MRI scans through its FDA-approved platform Quicktome, which is already in use at major hospitals and research institutions worldwide. The funding will support further commercialization of Quicktome, grow the company's data science team, develop next-generation clinical applications, and create 40 new highly skilled jobs in AI, neuroscience, and product development in Australia.Startup DailyNRF tips $20 million into brain mapping AI scaleup’s $36m Series DThe National Reconstruction Fund (NRF) has invested $20 million in neuroscience startup Omniscient Neurotechnology as part of a $36 million Series D funding round, co-leading the raise alongside OIF Ventures. Omniscient, founded in 2019, uses artificial intelligence to map individual brain connections from MRI scans, enabling neurosurgeons to personalise treatment plans rather than relying on generalised anatomical diagrams. The company's Quicktome platform has received US Food and Drug Administration approval and is already deployed at major hospitals and research institutions worldwide.Startup DailyNRF tips $20 million into brain mapping AI scaleup’s $36m Series DThe National Reconstruction Fund has invested $20 million in neuroscience startup Omniscient Neurotechnology as part of a $36 million Series D funding round co-led with OIF Ventures, taking a preferred equity stake. Omniscient uses AI to map brain connections from MRI scans through its FDA-approved platform Quicktome, which is already in use at major hospitals worldwide. The funding will support commercialization efforts, creation of 40 new highly skilled jobs in AI and neuroscience, and development of a connectomics center of excellence in Sydney with plans to expand in the US.Capital BriefNRF invests $20m in Omniscient Neurotechnology to lead Series D roundThe National Reconstruction Fund Corporation (NRF) has invested $20 million as a preferred equity stake in Omniscient Neurotechnology, co-leading a Series D funding round with OIF Ventures that is expected to raise up to $36 million total. The funding will accelerate commercialization of Omniscient's Quicktome platform, an AI-based brain-mapping technology that analyzes MRI scans to help doctors personalize patient treatment, and create over 40 new highly skilled jobs in AI, neuroscience, and product development. Omniscient, currently employing 16 people in Sydney, plans to establish a connectomics centre of excellence in Sydney and expand its US footprint, with Quicktome already approved by the FDA and in use at hospitals and research institutions globally.Business News AustraliaOmniscient Neurotechnology secures $20m towards Series DThe Australian government's National Reconstruction Fund Corporation (NRFC) has committed $20 million to Sydney-based Omniscient Neurotechnology (o8t) as part of a planned $36 million Series D round, following the company's US$60 million Series C in 2024. Omniscient's AI-powered brain mapping platform Quicktome, FDA-approved in 2021, helps neurosurgeons personalize treatment by generating detailed maps from MRI scans. The funding is expected to create over 40 new highly skilled jobs in Australia, support the establishment of a connectomics centre of excellence in Sydney, and help retain the company's intellectual property rights domestically while expanding globally.GlobeNewswireOmniscient Secures New CPT® Code for Connectomic Analysis, Validating the Clinical Utility of Brain Network MappingOmniscient announced that the American Medical Association has issued a new Category III CPT code (1039T) for connectomic analysis, effective July 1, 2026. This designation validates the clinical utility of brain network mapping and establishes a reporting pathway that facilitates future reimbursement for providers using Omniscient’s Quicktome software. The move supports broader adoption of connectomics in neurosurgical and neurological workflows by enabling data collection necessary for eventual Category I status.